ASP3082 in Patients With Solid Tumors and KRAS G12D Mutations

At ESMO Congress 2024, we met with Wungki Park, MD, MS, of Memorial Sloan Kettering Cancer Center, to discuss his trial on the use of ASP3082 in patients with solid tumors.

The investigational drug has shown positive outcomes in previously treated patients with pancreatic cancer and KRAS G12D mutations in the third-line setting.

Watch the second part of our interview with Dr. Park on the POLAR trial here.